{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T16:10:06Z","timestamp":1750176606847,"version":"3.41.0"},"reference-count":13,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T00:00:00Z","timestamp":1751328000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmedsci.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of the Medical Sciences"],"published-print":{"date-parts":[[2025,7]]},"DOI":"10.1016\/j.amjms.2025.03.012","type":"journal-article","created":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T03:52:49Z","timestamp":1743479569000},"page":"30-34","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluation of the efficacy of Omalizumab as re-treatment in patients with severe asthma"],"prefix":"10.1016","volume":"370","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4597-949X","authenticated-orcid":false,"given":"M\u00fcge","family":"Gen\u00e7er Tuluy","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7441-288X","authenticated-orcid":false,"given":"Yavuz","family":"Havlucu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9445-1598","authenticated-orcid":false,"given":"Deniz","family":"K\u0131z\u0131l\u0131rmak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4032-0944","authenticated-orcid":false,"given":"Ay\u015fe Arzu","family":"Yorganc\u0131o\u011flu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjms.2025.03.012_bib0001","unstructured":"Global Initiative of Asthma 2023 Report."},{"issue":"6","key":"10.1016\/j.amjms.2025.03.012_bib0002","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.amjms.2025.03.012_bib0003","doi-asserted-by":"crossref","first-page":"165","DOI":"10.3390\/jpm12020165","article-title":"Omalizumab: an optimal choice for patients with severe allergic asthma","volume":"12","author":"Kotoulas","year":"2022","journal-title":"J Pers Med"},{"issue":"4","key":"10.1016\/j.amjms.2025.03.012_bib0004","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.rmed.2014.02.003","article-title":"Observational study in severe asthmatic patients after discontinuation of omalizumab for good asthma control","volume":"108","author":"Molimard","year":"2014","journal-title":"Respir Med"},{"issue":"2","key":"10.1016\/j.amjms.2025.03.012_bib0005","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.anai.2015.05.010","article-title":"Outcomes of using omalizumab for >1 year in refractory chronic urticaria","volume":"115","author":"Har","year":"2015","journal-title":"Ann Allergy Asthma Immunol"},{"issue":"8","key":"10.1016\/j.amjms.2025.03.012_bib0006","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1136\/thoraxjnl-2017-210017","article-title":"Spanish Omalizumab Registry. Duration of the efficacy of omalizumab after treatment discontinuation in 'real life' severe asthma","volume":"73","author":"Vennera","year":"2018","journal-title":"Thorax"},{"issue":"1","key":"10.1016\/j.amjms.2025.03.012_bib0007","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.jaci.2016.08.054","article-title":"A randomized multicenter study evaluating Xolair persistence of response after long-term therapy","volume":"140","author":"Ledford","year":"2017","journal-title":"J Allergy Clin Immunol"},{"issue":"10","key":"10.1016\/j.amjms.2025.03.012_bib0008","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1159\/000525723","article-title":"Discontinuing omalizumab treatment in super-responder patients with allergic severe asthma: can the baseline total IgE level Be used as a biological marker to decide Discontinuing omalizumab treatment?","volume":"183","author":"Arslan","year":"2022","journal-title":"Int Arch Allergy Immunol"},{"issue":"2","key":"10.1016\/j.amjms.2025.03.012_bib0009","doi-asserted-by":"crossref","DOI":"10.1111\/dth.15248","article-title":"Analysis of clinical factors as possible predictors of response to omalizumab and relapse after treatment discontinuation in chronic spontaneous urticaria","volume":"35","author":"Foti","year":"2022","journal-title":"Dermatol Ther"},{"issue":"7","key":"10.1016\/j.amjms.2025.03.012_bib0010","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1016\/j.jaip.2020.03.022","article-title":"Omalizumab re-treatment and step-up in patients with chronic spontaneous urticaria: OPTIMA trial","volume":"8","author":"Sussman","year":"2020","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.amjms.2025.03.012_bib0011","doi-asserted-by":"crossref","first-page":"100","DOI":"10.23822\/EurAnnACI.1764-1489.136","article-title":"Omalizumab retreatment in patients with chronic spontaneous urticaria: a systematic review of published evidence","volume":"52","author":"Tonacci","year":"2020","journal-title":"Eur Ann Allergy Clin Immunol"},{"key":"10.1016\/j.amjms.2025.03.012_bib0012","doi-asserted-by":"crossref","first-page":"8191","DOI":"10.1038\/srep08191","article-title":"Long-term efficacy and safety of omalizumab in patients with persistent uncontrolled allergic asthma: a systematic review and meta-analysis","volume":"5","author":"Lai","year":"2015","journal-title":"Sci Rep"},{"issue":"7","key":"10.1016\/j.amjms.2025.03.012_bib0013","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.3390\/jpm13071068","article-title":"Long-term safety of Omalizumab in children with asthma and\/or chronic spontaneous urticaria: a 4-year prospective study in real life","volume":"13","author":"Galletta","year":"2023","journal-title":"J Pers Med"}],"container-title":["The American Journal of the Medical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925009802?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002962925009802?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,17]],"date-time":"2025-06-17T15:42:21Z","timestamp":1750174941000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002962925009802"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7]]},"references-count":13,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["S0002962925009802"],"URL":"https:\/\/doi.org\/10.1016\/j.amjms.2025.03.012","relation":{},"ISSN":["0002-9629"],"issn-type":[{"type":"print","value":"0002-9629"}],"subject":[],"published":{"date-parts":[[2025,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluation of the efficacy of Omalizumab as re-treatment in patients with severe asthma","name":"articletitle","label":"Article Title"},{"value":"The American Journal of the Medical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjms.2025.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Southern Society for Clinical Investigation. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}